What to Expect From Pfizer Earnings
Pfizer is scheduled to report its first-quarter financial results before the markets open on Tuesday.
Pfizer is scheduled to report its first-quarter financial results before the markets open on Tuesday.
With earnings having just been released for some of the top biotech companies, we saw a flurry of analyst calls by the week's end.
One portfolio manager on CNBC noted that Vertex could end up being an acquisition target ahead, without mentioning any specifics.
Molina Healthcare to a real beating after reporting a bad miss on first-quarter earnings. The stock was down nearly 20% on Friday.
Stericycle first-quarter financial results missed earnings expectations and the stock saw a new 52-week low early in Friday's session.
Gilead Sciences Inc. (NASDAQ: GILD) reported first-quarter financial results after the markets closed on Thursday. The company had $3.03 in earnings per share (EPS) on $7.79 billion in revenue compared to consensus estimates from…
Bristol-Myers Squibb released better-than-expected first-quarter financial results before the markets opened on Thursday.
AbbVie reported its first-quarter financial results and guidance before the markets opened on Thursday.
Spring Bank Pharmaceuticals expects to price more than a million shares in the range of $12 to $14 per share in an initial public offering valued up to more than $18 million.
The April 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest was mixed.
The April 15 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
If Moody's is correct, pharmaceutical earnings will keep growing for at least the next year and a half.
Catalyst Pharmaceuticals saw its shares get halved just Tuesday morning alone, following a business update regarding its Lambert-Eaton myasthenic syndrome treatment.
Typically each year, the first quarter is the slowest for biotech stocks. SunTrust Robinson Humphrey has four stocks rated Buy that should come in fine when numbers are released.
Eli Lilly is set to release its first-quarter earnings report before the markets open on Tuesday.